24242-21-5

Basic information

• Product Name: 5-Mercaptopyridine-3-carboxylic acid
• Synonyms: 5-Mercaptopyridine-3-carboxylic acid;5-Mercaptopyridine-3-Carboxylic Acid HCl
• CAS NO: 24242-21-5
• Molecular Formula: C6H5NO2S
• Molecular Weight: 155.1744
• Mol File: 24242-21-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 365 °C at 760 mmHg
• Flash Point: 174.6 °C
• Appearance: /
• Density: 1.439 g/cm³
• CAS DataBase Reference: 5-Mercaptopyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Mercaptopyridine-3-carboxylic acid(24242-21-5)
• EPA Substance Registry System: 5-Mercaptopyridine-3-carboxylic acid(24242-21-5)

Safety Data

• Hazardous Substances Data: 24242-21-5(Hazardous Substances Data)

Usage

General Description

5-Mercaptopyridine-3-carboxylic acid is a chemical compound with the molecular formula C6H5NO2S. It is a derivative of pyridine with a thiol group and a carboxylic acid group attached to the 3-position of the pyridine ring. 5-Mercaptopyridine-3-carboxylic acid is commonly used in the synthesis of pharmaceuticals, agrochemicals, and materials science. It is known for its ability to chelate with metal ions, making it useful in metal coordination chemistry. Additionally, 5-Mercaptopyridine-3-carboxylic acid has potential applications in the field of catalysis and as a reagent in organic synthesis. Overall, this compound has diverse uses in various industries and research applications.

Upstream product

• 885685-75-6 5-tert-butylsulfanylnicotinonitrile 
• 35590-37-5 5-bromopyridine-3-carbonitrile 
• 885685-76-7 5-tert-butylsulfanylnicotinic acid 

Relevant articles and documents

PITUITARY ADENYLATE CYCLASE ACTIVATING PEPTIDE (PACAP) RECEPTOR (VPAC2) AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the VPAC2 receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE

This invention provides peptides with novel modifications that provide suitable derivatization sites to improve the pharmacokinetic properties of the peptides. These modified peptides function in vivo as agonists of the GIP receptor. The peptides of the present invention provide a new therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics.

SELECTIVE NEUROPEPTIDE Y2 RECEPTOR AGONISTS

This invention provides peptides that act as selective NPY2 receptor agonists and may be used to reduce food intake. The invention includes a peptide selected from a specific group of derivatized NPY-related peptides, or functional equivalents thereof. The invention is also directed to a method of treating obesity or related diseases in a mammal comprising administering a therapeutically effective amount of the peptide to said mammal to reduce food intake and body weight.